HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CPSC nomination

This article was originally published in The Rose Sheet

Executive Summary

President Bush announces intention to nominate Harold Stratton to chair the Consumer Product Safety Commission Oct. 30. Albuquerque lawyer is "known consumer advocate" who served as Attorney General of New Mexico from 1987-1990 and was a member of New Mexico House of Representatives from 1979-1986, according to a White House spokesperson. Stratton currently is a partner with the law firm Stratton & Cavin (Albuquerque). Senate confirmation is required for the CPSC role; no hearings have yet been scheduled. The Bush Administration abandoned its push to appoint Mary Sheila Gall as chair after her nomination was defeated by Senate Democrats (1"The Rose Sheet" Aug. 6, In Brief)..

You may also be interested in...

CPSC leadership

Nomination of Harold Stratton to chair Consumer Product Safety Commission, take over as commissioner for remainder of term expiring Oct. 26, 2006, sent to the Senate March 13. Nomination will go before the Commerce Committee; no confirmation hearings have been scheduled. Bush Administration announced its choice in November, after Mary Sheila Gall's nomination was defeated by Senate Democrats (1"The Rose Sheet" Nov. 5, 2001, In Brief)...

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts